Targeting this peptide under non-treatment conditions could be a promising immunotherapeutic strategy, provided that the tumor relies on ST3GAL6 suppression and the generation of the RLSSSLPSR peptide as byproduct of this tumor promoting mechanism. Here, ST3GAL6 is linked to neoplasm.